bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas
Authors: Basu Devraj , Bewley Arnaud F. , Sperry Steven M. , Montone Kathleen T. , Gimotty Phyllis A. , Rasanen Kati , Facompre Nicole D. , Weinstein Gregory S. , Nakagawa Hiroshi , Diehl J. Alan , Rustgi Anil K. , Herlyn Meenhard
Published: April 2023

PDF file, 82K, Erlotinib resistance in mesenchymal-like SCC cells.
Supplementary Table 1 from New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib
Authors: Wei Yinxiang , Ma Yuanfang , Zhao Qing , Ren Zhiguang , Li Yan , Hou Tingjun , Peng Hui
Published: April 2023

PDF file, 103KB, Effect of sorafenib on ABCG2 ATPase activity.
Supplementary Figure 4 from New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib
Authors: Wei Yinxiang , Ma Yuanfang , Zhao Qing , Ren Zhiguang , Li Yan , Hou Tingjun , Peng Hui
Published: April 2023

PDF file, 108KB, Inhibition of ABCG2 function by sorafenib on mitoxantrone efflux.
Supplementary Table 1 from Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
Authors: Gunawardane Ruwanthi N. , Nepomuceno Ronald R. , Rooks Allison M. , Hunt Jeremy P. , Ricono Jill M. , Belli Barbara , Armstrong Robert C.
Published: April 2023

PDF file - 54K, Inhibition of FLT3 phosphorylation and cell viability by FLT3 inhibitors
Supplementary Figure 1 from Chemotherapy Counteracts Metastatic Dissemination Induced by Antiangiogenic Treatment in Mice
Authors: Rovida Alessandra , Castiglioni Vittoria , Decio Alessandra , Scarlato Valentina , Scanziani Eugenio , Giavazzi Raffaella , Cesca Marta
Published: April 2023

PDF - PDF 109K, Effect of sunitinib on metastatic Renca-luc tumors, orthotopic injection, neoadjuvant setting.
Supplementary Materials and Methods from The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models
Authors: Ning Yan , Labonte Melissa J. , Zhang Wu , Bohanes Pierre O. , Gerger Armin , Yang Dongyun , Benhaim Leonor , Paez David , Rosenberg David O. , Nagulapalli Venkata Kalyan C. , Louie Stan G. , Petasis Nicos A. , Ladner Robert D. , Lenz Heinz-Josef
Published: April 2023

PDF file - 111K
Supplementary Figure 3 from CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Authors: Salas Fragomeni Roberto A. , Chung Hye Won , Landesman Yosef , Senapedis William , Saint-Martin Jean-Richard , Tsao Hensin , Flaherty Keith T. , Shacham Sharon , Kauffman Michael , Cusack James C.
Published: April 2023

Supplementary Figure 3 - PDF 313K, CRM1 inhibition induces cell cycle arrest and increases cell death when combined with BRAF inhibition
Supplementary Figure 4 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
Authors: Chiron Marielle , Bagley Rebecca G. , Pollard Jack , Mankoo Parminder K. , Henry Christophe , Vincent Loïc , Geslin Catherine , Baltes Nina , Bergstrom Donald A.
Published: April 2023

PDF - 44K, Distribution of the tumor origin across PDX models: Of the 48 PDX tumors, 8 were derived from primary patient tumors, 36 from metastatic sites, 1 from a site of recurring disease, and 1 of unknown anatomical origin. All of the primary tumors (8/8) were associated with phenotype A where aflibercept is more efficacious than bevacizumab. PDX tumors that originated from metastatic tumors were represented in both phenotypes A (30/39) and B (9/9).
Supplementary Figure 2 from CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Authors: Salas Fragomeni Roberto A. , Chung Hye Won , Landesman Yosef , Senapedis William , Saint-Martin Jean-Richard , Tsao Hensin , Flaherty Keith T. , Shacham Sharon , Kauffman Michael , Cusack James C.
Published: April 2023

Supplementary Figure 2 - PDF 191K, CRM1 inhibition induces cell cycle arrest and increases cell death when combined with BRAF inhibition
Supplementary Figure 3 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
Authors: Chiron Marielle , Bagley Rebecca G. , Pollard Jack , Mankoo Parminder K. , Henry Christophe , Vincent Loïc , Geslin Catherine , Baltes Nina , Bergstrom Donald A.
Published: April 2023

PDF - 6683K, Tumor growth curves utilizing mean ATVs of the 48 CRC PDXs: Tumor growth curves for all 48 patient-derived CRC tumors in mice engrafted SC, and which were treated with aflibercept SC injection (2x/week, 25 mg/kg), vehicle (SC injection, 2x/week), or bevacizumab (IV injection, 2x/week, 25 mg/kg) for a total of 3 weeks. Tumor measurements were recorded twice per week. Error bars represent standard error of the mean.
Supplementary Figure 4 from Small Molecule Inhibition of PAX3-FOXO1 through AKT Activation Suppresses Malignant Phenotypes of Alveolar Rhabdomyosarcoma
Authors: Jothi Mathivanan , Mal Munmun , Keller Charles , Mal Asoke K.
Published: April 2023

PDF file - 535K, Supplementary Figure S4. Thapsigargin induces apoptotic DNA fragmentations in ARMS cells.
Supplementary Figure 3 from Small Molecule Inhibition of PAX3-FOXO1 through AKT Activation Suppresses Malignant Phenotypes of Alveolar Rhabdomyosarcoma
Authors: Jothi Mathivanan , Mal Munmun , Keller Charles , Mal Asoke K.
Published: April 2023

PDF file - 394K, Supplementary Figure S3. Thapsigargin but not dithiothreitol (DTT) decreases the expression levels of PAX3-FOXO1 protein in ARMS cells.
Supplementary Figure 2 from Small Molecule Inhibition of PAX3-FOXO1 through AKT Activation Suppresses Malignant Phenotypes of Alveolar Rhabdomyosarcoma
Authors: Jothi Mathivanan , Mal Munmun , Keller Charles , Mal Asoke K.
Published: April 2023

PDF file - 1972K, Supplementary Figure S2. Screen of primary hits for the identification of PAX3-FOXO1 inhibitors.
Supplementary Fig. S7 from Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
Authors: Tani Tetsuo , Yasuda Hiroyuki , Hamamoto Junko , Kuroda Aoi , Arai Daisuke , Ishioka Kota , Ohgino Keiko , Miyawaki Masayoshi , Kawada Ichiro , Naoki Katsuhiko , Hayashi Yuichiro , Betsuyaku Tomoko , Soejima Kenzo
Published: April 2023

The body weight of the mice after the treatment
Supplementary Fig. S6 from Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
Authors: Tani Tetsuo , Yasuda Hiroyuki , Hamamoto Junko , Kuroda Aoi , Arai Daisuke , Ishioka Kota , Ohgino Keiko , Miyawaki Masayoshi , Kawada Ichiro , Naoki Katsuhiko , Hayashi Yuichiro , Betsuyaku Tomoko , Soejima Kenzo
Published: April 2023

EGFR ligand induction in single cell derived H3122-AR clones
Supplementary Figures 1 - 6 from Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Authors: Knutson Sarah K. , Kawano Satoshi , Minoshima Yukinori , Warholic Natalie M. , Huang Kuan-Chun , Xiao Yonghong , Kadowaki Tadashi , Uesugi Mai , Kuznetsov Galina , Kumar Namita , Wigle Tim J. , Klaus Christine R. , Allain Christina J. , Raimondi Alejandra , Waters Nigel J. , Smith Jesse J. , Porter-Scott Margaret , Chesworth Richard , Moyer Mikel P. , Copeland Robert A. , Richon Victoria M. , Uenaka Toshimitsu , Pollock Roy M. , Kuntz Kevin W. , Yokoi Akira , Keilhack Heike
Published: April 2023

PDF file - 811K, Fig. S1. Effects of EPZ-6438 on Gene Promoter H3K27 Methylation, Recruitment of PRC2 Components to Gene Promoters, and Cell Cycle, in WSU-DLCL2 Cells. Fig. S2: Effects of EPZ-6438 on Gene Expression in EZH2 Mutant Lymphoma Cell Lines. Fig. S3: Pharmacokinetic Profiles of EPZ-6438 in Rats and Mice. Fig. S4: EPZ-6438 Compound Levels in Plasma and WSU-DLCL2 Xenograft Tumor Homogenates from Mice Dosed for 7 or 28 Days. Fig. S5: In vivo Effects of EPZ-6438 in Lymphoma Xenograft Models. Fig. S6: Body Weights of Mice during Xenograft Efficacy Studies.
Supplementary Figure 1 from Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer
Authors: Gharpure Kshipra M. , Chu Kevin S. , Bowerman Charles J. , Miyake Takahito , Pradeep Sunila , Mangala Selanere L. , Han Hee-Dong , Rupaimoole Rajesha , Armaiz-Pena Guillermo N. , Rahhal Tojan B. , Wu Sherry Y. , Luft J. Christopher , Napier Mary E. , Lopez-Berestein Gabriel , DeSimone Joseph M. , Sood Anil K.
Published: April 2023

PDF - 2261K, Characterization and efficacy of Chitosan nanoparticles.
Supplementary Figure 1 from Mutant Ras Elevates Dependence on Serum Lipids and Creates a Synthetic Lethality for Rapamycin
Authors: Salloum Darin , Mukhopadhyay Suman , Tung Kaity , Polonetskaya Aleksandra , Foster David A.
Published: April 2023

PDF - 2607K, Ras-driven cancer cells are uniquely dependent on exogenous fatty acids.
Supplementary Figure Legends from Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss
Authors: Beauchamp Ellen M. , Woods Brittany A. , Dulak Austin M. , Tan Li , Xu Chunxiao , Gray Nathanael S. , Bass Adam J. , Wong Kwok-kin , Meyerson Matthew , Hammerman Peter S.
Published: April 2023

PDF - 69KB.
Supplementary Table 1 from Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways
Authors: Garcia Khristofer , Blank Jonathan L. , Bouck David C. , Liu Xiaozhen J. , Sappal Darshan S. , Hather Greg , Cosmopoulos Katherine , Thomas Michael P. , Kuranda Mike , Pickard Michael D. , Liu Ray , Bandi Syamala , Smith Peter G. , Lightcap Eric S.
Published: April 2023

XLS file - 1161KB, Data Supporting Figures within Paper.
Supplementary Figure 5 from Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions
Authors: Mineharu Yohei , Kamran Neha , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

Supplementary Figure 5: Low dose Rapamycin does not enhance efficacy of Ad-Flt3L + Ad-TK/GCV
Supplementary Table 1 from Biochemical Assays for the Discovery of TDP1 Inhibitors
Authors: Marchand Christophe , Huang Shar-yin N. , Dexheimer Thomas S. , Lea Wendy A. , Mott Bryan T. , Chergui Adel , Naumova Alena , Stephen Andrew G. , Rosenthal Andrew S. , Rai Ganesha , Murai Junko , Gao Rui , Maloney David J. , Jadhav Ajit , Jorgensen William L. , Simeonov Anton , Pommier Yves
Published: April 2023

PDF - 65K, IC50 value table.
Supplementary Figure Legends from TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression
Authors: Zhu Jin , Yang Dong-Rong , Sun Yin , Qiu Xiaofu , Chang Hong-Chiang , Li Gonghui , Shan Yuxi , Chang Chawnshang
Published: April 2023

Supplementary Figure Legends
Supplementary Table 2 from Decreased miR-340 Expression in Bone Marrow Is Associated with Liver Metastasis of Colorectal Cancer
Authors: Takeyama Hiroshi , Yamamoto Hirofumi , Yamashita Shinya , Wu Xin , Takahashi Hidekazu , Nishimura Junichi , Haraguchi Naotsugu , Miyake Yasuhiro , Suzuki Rei , Murata Kohei , Ohue Masayuki , Kato Takeshi , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Hideshi , Mimori Koshi , Doki Yuichiro , Mori Masaki
Published: April 2023

PDF - 63K, miR-340 expression and clinicopathologic factors.
Supplementary Figure S2 from TLR4 Is a Novel Determinant of the Response to Paclitaxel in Breast Cancer
Authors: Rajput Sandeep , Volk-Draper Lisa D. , Ran Sophia
Published: April 2023

Supplementary Figure S2 - PDF file 188K, Expression of TLR receptors in MDA-MB-231 and HCC1806 cells
Supplementary methods and legends from 1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
Authors: Chen Ping-Tsung , Hsieh Ching-Chuan , Wu Chun-Te , Yen Tzu-Chen , Lin Paul-Yang , Chen Wen-Cheng , Chen Miao-Fen
Published: April 2023

Supplementary methods and legends for supplementary Figures
Supplementary Figure 5 from 1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
Authors: Chen Ping-Tsung , Hsieh Ching-Chuan , Wu Chun-Te , Yen Tzu-Chen , Lin Paul-Yang , Chen Wen-Cheng , Chen Miao-Fen
Published: April 2023

Supplementary Figure 5. IL-6 levels in 4-NQO-treated mice with or without Calcitriol or IL-6 injection were measured using ELISA
Supplementary Figures 1 - 4 from Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Authors: Murai Junko , Huang Shar-Yin N. , Renaud Amèlie , Zhang Yiping , Ji Jiuping , Takeda Shunichi , Morris Joel , Teicher Beverly , Doroshow James H. , Pommier Yves
Published: April 2023

PDF file - 1641K, Supplementary figure 1. Stereospecific targeting of PARP by BMN 673. Supplementary figure 2. Lack of effect of PARP inhibition on ATP concentration. Supplementary figure 3. Flow cytometry analyses after treatment with different PARP inhibitors. Supplementary figure 4. Stereospecific poisoning of PARP by BMN 673.
Supplementary Figures 1 through 6 from Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling
Authors: Balic Anamaria , Sørensen Morten Dræby , Trabulo Sara Maria , Sainz Bruno , Cioffi Michele , Vieira Catarina R. , Miranda-Lorenzo Irene , Hidalgo Manuel , Kleeff Joerg , Erkan Mert , Heeschen Christopher
Published: April 2023

PDF - 3180K, Figure S1. Chloroquine does not affect differentiated cancer cells. Figure S2. Chloroquine eliminates pancreatic cancer stem cells. Figure S3. Autophagy is not mediating the effect of chloroquine on primary PDAC cells. Figure S4. Chloroquine has no effect on cell migration of non-CSCs Figure S5 - Chloroquine displays negative in vitro effect on the Shh signaling. Figure S6. Inhibitory in vivo effect of chloroquine on stromal hedgehog signaling and expansion of the stroma.
Supplementary Tables 1 - 7 from Phosphoproteomics of MAPK Inhibition in BRAF-Mutated Cells and a Role for the Lethal Synergism of Dual BRAF and CK2 Inhibition
Authors: Parker Robert , Clifton-Bligh Roderick , Molloy Mark P.
Published: April 2023

XLSX file - 3733K, Sup. Tab. 1. Phosphosite localization statistical analysis with Scaffold PTM. Sup. Tab. 2. NetworKIN Kinase substrate relationship prediction for all sites identified. Sup. Tab. 3. Raw Peak area data generated by Skyline by label free quantitation (LFQ). Sup. Tab. 4. Statistical analysis of LFQ data using DanteR software. Sup. Tab. 5. Ingenuity Pathway analysis of phosphopeptides identified by LC-MS. Sup. Tab. 6. Parallel reaction monitoring (PRM)quantitative data and statistical analysis. Sup. Tab. 7. Cell viability data.
Legend for Supplemental Figure 1 from A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts
Authors: Becker Marc A. , Haluska Paul , Bale Laurie K. , Oxvig Claus , Conover Cheryl A.
Published: April 2023

Legend for Supplemental Figure 1
Supplementary Figure 1 from Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
Authors: Liu Yingmiao , Starr Mark D. , Brady John C. , Rushing Christel , Bulusu Anuradha , Pang Herbert , Honeycutt Wanda , Amara Anthony , Altomare Ivy , Uronis Hope E. , Hurwitz Herbert I. , Nixon Andrew B.
Published: April 2023

Hierarchical clustering analyses may identify potential patterns of marker expression and biologically relevant groupings. As an example, PDGF-AA and PDGF-BB are tightly clustered at baseline, indicating that if a patient had high PDGF-AA levels, PDGF-BB levels also tended to be high. This relationship is maintained at later time points (C2D1 and C3D1), as the clustering of PDGFs reflects similar patterns of change on-treatment.
Supplementary Table 2 from Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro
Authors: Wu Xuping , Sooman Linda , Wickström Malin , Fryknäs Mårten , Dyrager Christine , Lennartsson Johan , Gullbo Joachim
Published: April 2023

PDF file - 23K, Table S2. The phenotypic ten cell-line panel.
Supplementary Figure 4 from Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro
Authors: Wu Xuping , Sooman Linda , Wickström Malin , Fryknäs Mårten , Dyrager Christine , Lennartsson Johan , Gullbo Joachim
Published: April 2023

PDF file - 48K, Figure S4 The activity of PPP at 10 μM did not correlate with the expression (A) or phosphorylation (B) of IGF-1R (p>0.05) in eight lung cancer cell lines.
Supplementary Tables 1 through 13 and Supplementary Table 15 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
Authors: Xia Junfeng , Jia Peilin , Hutchinson Katherine E. , Dahlman Kimberly B. , Johnson Douglas , Sosman Jeffrey , Pao William , Zhao Zhongming
Published: April 2023

PDF - 160K, Supplementary Table S1. Summary of the six next-generation sequencing (NGS) studies containing 241 paired melanoma tumor/normal samples. Supplementary Table S2. Summary of known driver mutations detected in the 241 melanoma samples. Table S3. Mutated genes significantly associated with BRAF-mutated samples (frequencygreater than or equal to 10% and p-value < 0.05) in the Hodis et al. study. Table S4. Mutated genes significantly associated with NRAS-mutated samples (frequencygreater than or equal to 10% and p-value < 0.05) in the Hodis et al. study. Table S5. Mutated genes significantly associated with BRAF-mutated samples (frequencygreater than or equal to 10% and p-value < 0.05) in the Krauthammer et al. study. Table S6. Mutated genes significantly associated with NRAS-mutated samples (frequencygreater than or equal to 10% and p-value < 0.05) in the Krauthammer et al. study. Table S7. Mutated genes significantly associated with BRAF-mutated samples identified by the meta-analysis but not significantly BRAF-associated in the Hodis et al. study (corresponds with Table 1). Table S8. Mutated genes significantly associated with NRAS-mutated samples identified by the meta-analysis but some of them not significantly NRAS-associated in the Hodis et al. study (corresponds with Table 2). Table S9. Mutated genes significantly associated with BRAF-mutated samples as identified by the meta-analysis but not significantly BRAF-associated in the Krauthammer et al. study (corresponds with Table 1). Table S10. Mutated genes significantly associated with NRAS-mutated samples as identified by the meta-analysis but most of them not significantly NRAS-associated in the Krauthammer et al. study. Supplementary Table S11. Meta-analysis defined mutated genes associated with BRAF-mutated samples (frequencygreater than or equal to 10%, p-value < 0.05 is shown in red) by histological subtype. Supplementary Table S12. Meta-analysis defined mutated genes associated with NRAS-mutated samples (frequencygreater than or equal to 10%, p-value < 0.05 is shown in red) by histological subtype. Supplementary Table S13. Meta-analysis identified guanine nucleotide-binding protein alpha-subunit (GNA) mutations in the 69 pan-negative melanoma samples. Table S15. Summary of Meta-analysis identified genes with mutations enriched in pan-negative sun-exposed melanoma samples (mutation frequency greater than or equal to 10% and p-value < 0.05).
Data Supplement from Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na
Authors: Mäki-Jouppila Jenni H.E. , Laine Leena J. , Rehnberg Jonathan , Narvi Elli , Tiikkainen Pekka , Hukasova Elvira , Halonen Pasi , Lindqvist Arne , Kallio Lila , Poso Antti , Kallio Marko J.
Published: April 2023

Supplemental Movie 5. Microtubule dynamicity in a control A549 cell stably expressing EGFP-alpha-tubulin. Cells were treated with DMSO for 1 h before the analysis of microtubule dynamicity using 10 s frame capture interval for a total of 4 min. For the analysis, microtubule plus-ends were marked (blue dots) and the total growth and shrinkage velocities of individual microtubules were measured.
Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
Authors: Xia Junfeng , Jia Peilin , Hutchinson Katherine E. , Dahlman Kimberly B. , Johnson Douglas , Sosman Jeffrey , Pao William , Zhao Zhongming
Published: April 2023

XLSX - 28K, Supplementary Table S14. Mutations in 12 potential cancer genes in pan-negative melanoma samples.
Supplementary Figure 1 from Novel Curcumin-Loaded Magnetic Nanoparticles for Pancreatic Cancer Treatment
Authors: Yallapu Murali M. , Ebeling Mara C. , Khan Sheema , Sundram Vasudha , Chauhan Neeraj , Gupta Brij K. , Puumala Susan E. , Jaggi Meena , Chauhan Subhash C.
Published: April 2023

PDF file - 126K, MNP-CUR nanoparticles efficiently internalize in cancer cells.
Supplementary Figure 1 from Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF-β, and Wnt Signaling Pathways
Authors: Basu Dipanjan , Lettan Robert , Damodaran Krishnan , Strellec Susan , Reyes-Mugica Miguel , Rebbaa Abdelhadi
Published: April 2023

PDF - 102K, Chemical synthesis of C19.
Supplementary Table 1; Figures 1-4 from Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair
Authors: Kryeziu Kushtrim , Jungwirth Ute , Hoda Mir Alireza , Ferk Franziska , Knasmüller Siegfried , Karnthaler-Benbakka Claudia , Kowol Christian R. , Berger Walter , Heffeter Petra
Published: April 2023

PDF File - 512K, Solid cancer cell lines and their genetic characteristics.
Supplementary Figures 1 - 7 from IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy
Authors: Ferté Charles , Loriot Yohann , Clémenson Céline , Commo Frederic , Gombos Andrea , Bibault Jean-Emmanuel , Fumagalli Ingrid , Hamama Saad , Auger Nathalie , Lahon Benoit , Chargari Cyrus , Calderaro Julien , Soria Jean-Charles , Deutsch Eric
Published: April 2023

PDF file - 391K, Supplementary figure 1: Effect of R1507 (18mg/kg/week), Cisplatin (3mg/kg/week) for a total of 3 injections on day 1, 8 and 15) and combination of both treatments on H526 (A) and H146 (B) xenografts in nude mice Effect of R1507 (18mg/kg/week), ionizing radiation (4 fractions of 2 Gy; days 1-4) and combination of both treatments on H526 xenografts in Nude mice (C).Supplementary figure 2: Kaplan-Meier plots showing the tumor progression of nude mice with H146 xenografts. Supplementary figure 3: Heatmap depicting the mean fold-change for the 94 probe sets that are significantly differentially expressed (2 fold change, P < 0.05, Benjamini Hochberg adjusted) at R1507 day 7 only or that exhibit an inversion of R1507 day gene expression profile. Supplementary figure 4: Effect of short- and prolonged-R1507 exposure on the protein expression of selected receptor tyrosine kinase and intracellular nodes as captured by the PathScan RTK Signaling Antibody Array (see Supplementary Methods). Supplementary figure 5: Heatmap depicting the mean fold-change for the 399 probe sets that are significantly differentially expressed under R1507 + Cisplatin Cisplatin (two-way ANOVA, P<.05, Benjamini Hochberg adjusted). Supplementary figure 6: Heatmap depicting the mean fold-change for the 31 probe sets that are significantly differentially expressed under R1507 + Cisplatin (two-way ANOVA, P<.05, Benjamini Hochberg adjusted). Supplementary figure 7: (A) Effect of R1507 (200 nM), Cisplatin (3M) (CDDP) and combination of both on ERCC1 and XPA protein expression in H526 cell lines (Western Blots). (B) Effect of R1507 (200 nM), Ionizing radiation (IR) (2Gy) and combination of both on ERCC1 and XPA protein expression in H526 cell lines (Western Blots). (C) Effect of R1507 (200 nM), Cisplatin (3M) (CDDP) and combination of both on cleaved caspase 9 protein expression in H526 cell lines (Western Blots). (D) Effect of R1507 (200 nM), Ionizing radiation (IR) (2Gy) and combination of both on cleaved caspase 9 protein expression in H526 cell lines (Western Blots).
Supplementary Table 1 from Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Authors: Ihnen Maike , zu Eulenburg Christine , Kolarova Teodora , Qi Jing Wei , Manivong Kanthinh , Chalukya Meenal , Dering Judy , Anderson Lee , Ginther Charles , Meuter Alexandra , Winterhoff Boris , Jones Siân , Velculescu Victor E. , Venkatesan Natarajan , Rong Hong-Mei , Dandekar Sugandha , Udar Nitin , Jänicke Fritz , Los Gerrit , Slamon Dennis J. , Konecny Gottfried E.
Published: April 2023

PDF file - 66K, Cell lines and culture media.
Supplementary Figure S3 from Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Authors: Govindan Serengulam V. , Cardillo Thomas M. , Sharkey Robert M. , Tat Fatma , Gold David V. , Goldenberg David M.
Published: April 2023

PDF file - 718 KB, (A) Release of doxorubicin from milatuzumab (hLL1)-doxorubicin conjugate at pH 5, 37 degrees Celsius and (B) in serum at 37 degrees Celsius
Supplementary Table 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Authors: Ning Yan , Gerger Armin , Zhang Wu , Hanna Diana L. , Yang Dongyun , Winder Thomas , Wakatsuki Takeru , Labonte Melissa J. , Stintzing Sebastian , Volz Nico , Sunakawa Yu , Stremitzer Stefan , El-Khoueiry Rita , Lenz Heinz-Josef
Published: April 2023

PDF - 86KB, LCP1 polymorphisms and outcome in patients with stage II or III colon cancer (USC cohort).
Supplementary Figure 4 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Authors: Ning Yan , Gerger Armin , Zhang Wu , Hanna Diana L. , Yang Dongyun , Winder Thomas , Wakatsuki Takeru , Labonte Melissa J. , Stintzing Sebastian , Volz Nico , Sunakawa Yu , Stremitzer Stefan , El-Khoueiry Rita , Lenz Heinz-Josef
Published: April 2023

PDF - 43KB, Plastin protein expression from plasma of stage II/III CRC patients. ELISA quantitated LCP1 and PLS3 protein level in USC cohort patients' serum. The significance in expression level was determined by the GraphPad Prism software. Data shown represent the mean ? standard deviation. P <0.05 was considered significant. Stage of colorectal cancer was classified according to TNM staging system. Supplementary figure 4 method: ELISA: Microtiter 96-well plates were coated with patient plasma samples in 50 mM carbonate buffer at a pH of 9.0 and incubated overnight. The quantification of PLS3 (A-8, SC-166223, 1μg/ml) and LCP1 (B-9, SC-133218, 1μg/ml) protein was determined using the protocol provided by Santa Cruz Technology. Standard 1000, 500, 250, 15, 62.5, 31.25, 15.625, 7.8125, 3.9, 1.95 ng/ml dilutions of PLS3 and LCP1 were prepared, and the corresponding optical density (OD) values were used to prepare a standard curve using the Origin 6.1 software.
Supplementary Figure 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Authors: Ning Yan , Gerger Armin , Zhang Wu , Hanna Diana L. , Yang Dongyun , Winder Thomas , Wakatsuki Takeru , Labonte Melissa J. , Stintzing Sebastian , Volz Nico , Sunakawa Yu , Stremitzer Stefan , El-Khoueiry Rita , Lenz Heinz-Josef
Published: April 2023

PDF - 56KB, Time-to-tumor recurrence (TTR) by LCP111342 in USC cohort (Training set) stage II/III CRC male patients treated with 5-fluorouracil (5-FU)-based chemotherapy.
Supplementary Table 4 from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Authors: Xiao Yang , Ramiscal Judi , Kowanetz Kaska , Del Nagro Christopher , Malek Shiva , Evangelista Marie , Blackwood Elizabeth , Jackson Peter K. , O'Brien Thomas
Published: April 2023

PDF - 46KB, Bliss scores for each combination of agent and GNE-783 across a panel of cell lines.
Supplementary Figure 1 from Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport
Authors: Kuzu Omer F. , Gowda Raghavendra , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 66K, Abietic acid a structurally similar compound to leelamine without an amine group fails to induce vacuolization and death of melanoma cells.
Supplementary Figure 3 from Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing β-Catenin Signaling
Authors: Jin Bei , Ding Ke , Pan Jingxuan
Published: April 2023

PDF file - 137KB, Immunohistochemical analysis of the in vivo signaling in xenograft tumors.
Supplementary Figure 3 from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Authors: Xiao Yang , Ramiscal Judi , Kowanetz Kaska , Del Nagro Christopher , Malek Shiva , Evangelista Marie , Blackwood Elizabeth , Jackson Peter K. , O'Brien Thomas
Published: April 2023

PDF - 43KB, In vivo potentiation of gemcitabine, SN-38, and TMZ wiht GNE-900.
Supplementary Notes from Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Authors: Happold Caroline , Roth Patrick , Silginer Manuela , Florea Ana-Maria , Lamszus Katrin , Frei Karl , Deenen Rene , Reifenberger Guido , Weller Michael
Published: April 2023

PDF file - 84KB, 1) MGMT expression in GIC lines 2) IFN-beta sensitizes glioma cells to TMZ and irradiation independently of MGMT or TP53.
Supplementary Figure 1 from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Authors: Xiao Yang , Ramiscal Judi , Kowanetz Kaska , Del Nagro Christopher , Malek Shiva , Evangelista Marie , Blackwood Elizabeth , Jackson Peter K. , O'Brien Thomas
Published: April 2023

PDF - 339KB, Profile of Bliss scores for each indicated agent in combination with GNE-783.
Supplementary Figure 4 from Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Authors: Happold Caroline , Roth Patrick , Silginer Manuela , Florea Ana-Maria , Lamszus Katrin , Frei Karl , Deenen Rene , Reifenberger Guido , Weller Michael
Published: April 2023

PDF file - 502KB, IFN-beta-induced sensitization of LTL glioma cells to TMZ and irradiation: no modulation by MGMT or TP53.
Supplementary Table 1 from Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro
Authors: Hu Jinsong , Van Valckenborgh Els , Xu Dehui , Menu Eline , De Raeve Hendrik , De Bryune Elke , Xu Song , Van Camp Ben , Handisides Damian , Hart Charles P. , Vanderkerken Karin
Published: April 2023

PDF file - 117 KB, Combination index analysis of TH-302 combined with bortezomib at a non-constant ratio in OPM2 cells.
Supplementary Table 4D from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

XLSX - 1181K, Table S4D. Differentially expressed genes between Control Vs. LiCl treated cells.
Supplementary Table 4B from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

XLSX - 305K, Table S4B. Differentially expressed genes between Control Vs. Azakenpaullone treated cells.
Supplementary Figure 2 from Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma
Authors: Zovko Ana , Viktorsson Kristina , Hååg Petra , Kovalerchick Dimitry , Färnegårdh Katarina , Alimonti Andrea , Ilan Micha , Carmeli Shmuel , Lewensohn Rolf
Published: April 2023

Supplementary Figure 2: The cytotoxicity of 1 and 2 was examined in NSCLC U-1810 and normal lung fibroblasts (WI-38) following 24 h and 48 h of continuous exposure using MTT assay. Cell viability is given as % of cell survival as compared to DMSO solvent treated cells. Data shown is the mean of three independent experiments {plus minus}SEM. The IC30, IC50 and IC70 concentrations are given in Supplementary Table S3.
Supplementary Figures S1-S3, Tables S1-S7 from CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
Authors: Mortensen Deborah S. , Fultz Kimberly E. , Xu Shuichan , Xu Weiming , Packard Garrick , Khambatta Godrej , Gamez James C. , Leisten Jim , Zhao Jingjing , Apuy Julius , Ghoreishi Kamran , Hickman Matt , Narla Rama Krishna , Bissonette Rene , Richardson Samantha , Peng Sophie X. , Perrin-Ninkovic Sophie , Tran Tam , Shi Tao , Yang Wen Qing , Tong Zeen , Cathers Brian E. , Moghaddam Mehran F. , Canan Stacie S. , Worland Peter , Sankar Sabita , Raymon Heather K.
Published: April 2023

Supplementary Figures S1-S3, Tables S1-S7. Suppl. Figure S1: Prolif. Curves, PC3 Cell Cycle & solid tumor apoptosis Suppl. Figure S2: PK/PD Model Performance and eIF4E In Vivo Biomarker Suppl. Figure S3: HCT-116, MBA MD231 & A549 Efficacy Studies Suppl. Table S1: Kinase Selectivity Suppl. Table S2: Cellular Biomarker with SEM Suppl. Table S3: Cellular Proliferation with SEM Suppl. Table S4: Hematological Panel Suppl. Table S5: IRF4 Gene and Protein Data Suppl. Table S6: PK/PD Data PK Data Suppl. Table S7: In Vivo Efficacy Across Tumor Types
Supplementary Figure 3 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Authors: Fritsch Christine , Huang Alan , Chatenay-Rivauday Christian , Schnell Christian , Reddy Anupama , Liu Manway , Kauffmann Audrey , Guthy Daniel , Erdmann Dirk , De Pover Alain , Furet Pascal , Gao Hui , Ferretti Stephane , Wang Youzhen , Trappe Joerg , Brachmann Saskia M. , Maira Sauveur-Michel , Wilson Christopher , Boehm Markus , Garcia-Echeverria Carlos , Chene Patrick , Wiesmann Marion , Cozens Robert , Lehar Joseph , Schlegel Robert , Caravatti Giorgio , Hofmann Francesco , Sellers William R.
Published: April 2023

PDF - 92K, NVP-BYL719 does not inhibit mTOR and PIKKs involved in DNA damage-repair processes. A. TSC1 -/- MEFs cells were grown in a 96-well format and treated for 1 h with increased concentrations of RAD001 or NVP-BYL719 (from 0.5 nmol/L to 10 ?mol/L in 1 third dilution steps) and immediately fixed. S235/236P-RPS6 levels were measured and IC50 determined with the Excel module XLfit. Background (no primary Ab incubated); BL, Baseline. B: TSC1 -/- MEFs cells were treated with increasing concentrations of NVP-BYL719 as indicated or RAD001 at 500 nmol/L or an equivalent DMSO concentration for 30 minutes. Levels of S235/236P-RPS6 and total RPS6 in protein- normalized lysates were detected by Western blot analyzis using an activation-state specific antibody, followed by incubation with species- specific HRP-labeled secondary antibody and signal development by ECL. C: 24 h post seeding, A549 cells were treated at the same time with Actinomycin D (Act D) at a concentration of 5 ?mol/L (an agent used to induce DNA damage), and with increasing concentrations of NVP-BYL719 as indicated or with the vehicle control (DMSO) for 1 h. Levels of S15P-p53 and tubulin in protein-normalized lysates were detected by Western blot analysis using an activation-state specific antibody, followed by incubation with species- specific HRP-labeled secondary antibody and signal development by ECL. D: 24 h post seeding, U2OS cells were pre-treated for 1 h with increased concentrations of NVP-BYL719 or KU55933 a specific small molecular mass inhibitor of ATM (Supplementary reference 1) at a concentration of 10 ?mol/L or with the vehicle control (DMSO). The cells were then irradiated with 15 Gy and re-incubated at 37 degrees C for 1 h and then lysed. Levels of S1981P-ATM in protein- normalized lysates were detected by Western blot analysis using an activation-state specific antibody, followed by incubation with species- specific HRP-labeled secondary antibody and signal development by ECL.
Supplementary Figure Legend from Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis
Authors: Petruccelli Luca A. , Pettersson Filippa , del Rincón Sonia V. , Guilbert Cynthia , Licht Jonathan D. , Miller Wilson H.
Published: April 2023

PDF file - 87K
Supplementary Figure 6 from Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis
Authors: Petruccelli Luca A. , Pettersson Filippa , del Rincón Sonia V. , Guilbert Cynthia , Licht Jonathan D. , Miller Wilson H.
Published: April 2023

PDF file - 3363K, The effect of leukemia associated fusion proteins and HDAC inhibitors on base excision repair and DNA double strand break repair genes.
Supplementary Figure 1 from An Autocrine Loop between TGF-β1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype
Authors: Larocca Cecilia , Cohen Joseph R. , Fernando Romaine I. , Huang Bruce , Hamilton Duane H. , Palena Claudia
Published: April 2023

PDF file - 89K, TGF-β1 secretion in LNCap and H520 cells.
Supplementary Figure 3 from Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis
Authors: Petruccelli Luca A. , Pettersson Filippa , del Rincón Sonia V. , Guilbert Cynthia , Licht Jonathan D. , Miller Wilson H.
Published: April 2023

PDF file - 3534K, The effects of PLZF-RARα and vorinostat on DNA damage and cell cycle regulators.
Supplementary Tables 1 and 2 and Supplementary Figures 1 through 6 from Increasing the Antitumor Effect of an EpCAM-Targeting Fusion Toxin by Facile Click PEGylation
Authors: Simon Manuel , Stefan Nikolas , Borsig Lubor , Plückthun Andreas , Zangemeister-Wittke Uwe
Published: April 2023

PDF - 425KB, Table S1: Affinities of Ec1-ETA", Aha-Ec1-ETA" and PEG20kDa-Ec1-ETA" determined by surface plasmon resonance (SPR) on immobilized EpCAM. Table S2: Cytotoxicity of fusion toxins against EpCAM-positive tumor cell lines. Figure S1: Purification of PEGylated ETA" fusion toxins by anion exchange chromatography (A, B) followed by preparative size exclusion chromatography (C, D). Figure S2: Anion exchange chromatography of fusion toxin. Figure S3: Comparison of Ec1-ETA" and PEG20kDa-Ec1-ETA" by analytical size exclusion chromatography (aSEC). Figure S4: Effect of N-terminal click-PEGylation on the affinity of Ec1-ETA". Figure S5: Characterization of PEGylated Ec1-ETA" containing an N-terminal 3C (PreScission) protease site for proteolytic removal of the polymer.Figure S6: In vitro serum stability of fusion toxins.
Supplementary Table 1 from BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Authors: Kutluk Cenik Bercin , Ostapoff Katherine T. , Gerber David E. , Brekken Rolf A.
Published: April 2023

PDF - 31KB, Supplemental table of antibodies.
Supplementary Figure 1 from Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs
Authors: Stella Stefania , Tirrò Elena , Conte Enrico , Stagno Fabio , Di Raimondo Francesco , Manzella Livia , Vigneri Paolo
Published: April 2023

PDF file - 96K, YM155 sensitizes primary leukemic cells isolated from CML patients to different tyrosine-kinase inhibitors.
Supplementary Materials and Methods from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Authors: Fitzgerald Jonathan B. , Johnson Bryan W. , Baum Jason , Adams Sharlene , Iadevaia Sergio , Tang Jian , Rimkunas Victoria , Xu Lihui , Kohli Neeraj , Rennard Rachel , Razlog Maja , Jiao Yang , Harms Brian D. , Olivier Kenneth J. , Schoeberl Birgit , Nielsen Ulrik B. , Lugovskoy Alexey A.
Published: April 2023

PDF - 111K, Additional details on the implementation and training of the mechanistic model.
Supplementary Figure 1 and Supplementary Table 1 from Preclinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas
Authors: Dave Nimita , Chow Lionel M.L. , Gudelsky Gary A. , LaSance Kathleen , Qi Xiaoyang , Desai Pankaj B.
Published: April 2023

Supplementary Figure 1. Correlation between observed cytotoxicity (MTT assay) and Inhibition of Aromatase Activity (EIA assay). Supplementary Table 1. Active tumor volumes obtained from μPET/CT scans of individual rats from control and treatment groups.
Supplementary Figure Legend from ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer
Authors: Zinn Rebekah L. , Gardner Eric E. , Marchionni Luigi , Murphy Sara C. , Dobromilskaya Irina , Hann Christine L. , Rudin Charles M.
Published: April 2023

PDF file - 71K
Supplementary Table 4 from Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Authors: Stessman Holly A.F. , Baughn Linda B. , Sarver Aaron , Xia Tian , Deshpande Raamesh , Mansoor Aatif , Walsh Susan A. , Sunderland John J. , Dolloff Nathan G. , Linden Michael A. , Zhan Fenghuang , Janz Siegfried , Myers Chad L. , Van Ness Brian G.
Published: April 2023

PDF file - 59K, Unique gene predictors of the panobinostat response in bortezomib-resistant mouse cell lines.
Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Authors: Li Dongwei , Poon Kirsten Achilles , Yu Shang-Fan , Dere Randall , Go MaryAnn , Lau Jeffrey , Zheng Bing , Elkins Kristi , Danilenko Dimitry , Kozak Katherine R. , Chan Pamela , Chuh Josefa , Shi Xiaoyan , Nazzal Denise , Fuh Franklin , McBride Jacqueline , Ramakrishnan Vanitha , de Tute Ruth , Rawstron Andy , Jack Andrew S. , Deng Rong , Chu Yu-Waye , Dornan David , Williams Marna , Ho William , Ebens Allen , Prabhu Saileta , Polson Andrew G.
Published: April 2023

XLSX file - 30K, IC50 concentrations and CD22 expression levels for cell lines.
Supplementary Figure 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Authors: Li Dongwei , Poon Kirsten Achilles , Yu Shang-Fan , Dere Randall , Go MaryAnn , Lau Jeffrey , Zheng Bing , Elkins Kristi , Danilenko Dimitry , Kozak Katherine R. , Chan Pamela , Chuh Josefa , Shi Xiaoyan , Nazzal Denise , Fuh Franklin , McBride Jacqueline , Ramakrishnan Vanitha , de Tute Ruth , Rawstron Andy , Jack Andrew S. , Deng Rong , Chu Yu-Waye , Dornan David , Williams Marna , Ho William , Ebens Allen , Prabhu Saileta , Polson Andrew G.
Published: April 2023

PDF file - 61K, Supplemental Figure 1. Human, cynomolgus monkey, and rat PBMCs were isolated from whole blood in accordance with BD Vacutainer CPT protocol. Mouse PBMCs were isolated from whole blood by ACK lysis buffer treatment to lyse red blood cells followed by centrifucation to recover PBMCs. Human antibodies were labeled in accordance with the protocol with Zenon Alexa Fluor 647 Human IgG Labeling Kit. Mean fluorescent intensity (MFI) was calculated from the CD20‑positive B cells (human and cynomolgus monkey), CD45RA‑positive B cells (rat), or CD45R‑positive B cells (mouse).
Supplementary Methods from Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Authors: Stessman Holly A.F. , Baughn Linda B. , Sarver Aaron , Xia Tian , Deshpande Raamesh , Mansoor Aatif , Walsh Susan A. , Sunderland John J. , Dolloff Nathan G. , Linden Michael A. , Zhan Fenghuang , Janz Siegfried , Myers Chad L. , Van Ness Brian G.
Published: April 2023

PDF file - 76K
Supplementary Figure 4 from Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Authors: Stessman Holly A.F. , Baughn Linda B. , Sarver Aaron , Xia Tian , Deshpande Raamesh , Mansoor Aatif , Walsh Susan A. , Sunderland John J. , Dolloff Nathan G. , Linden Michael A. , Zhan Fenghuang , Janz Siegfried , Myers Chad L. , Van Ness Brian G.
Published: April 2023

PDF file - 1297K, Quantitative RT-PCR and histologic analysis of differences between sensitive and resistant mouse cell lines.
Supplementary Figure 1 from Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Authors: Stessman Holly A.F. , Baughn Linda B. , Sarver Aaron , Xia Tian , Deshpande Raamesh , Mansoor Aatif , Walsh Susan A. , Sunderland John J. , Dolloff Nathan G. , Linden Michael A. , Zhan Fenghuang , Janz Siegfried , Myers Chad L. , Van Ness Brian G.
Published: April 2023

PDF file - 166K, Bortezomib death profiles of mouse and human plasma cell lines for gene expression profiling.
Supplementary Figure 4 from Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer
Authors: Wei Ning , Chu Edward , Wipf Peter , Schmitz John C.
Published: April 2023

PDF - 148K, Fig S4. Effect of PKD inhibitor on clonal formation.
Supplementary Figure 2 from Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer
Authors: Wei Ning , Chu Edward , Wipf Peter , Schmitz John C.
Published: April 2023

PDF - 142K, Fig. S2. PKD1, PKD2 and PKD3 mRNA expression in cell lines from the Cancer Cell Line Encyclopedia database.
Supplementary Figure 1 from Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer
Authors: Wei Ning , Chu Edward , Wipf Peter , Schmitz John C.
Published: April 2023

PDF - 54K, Fig. S1. PKD1, PKD2 and PKD3 mRNA expression in colon cancer cells lines from the CellMiner database.
Supplementary Figure 4 from Inhibition of mTOR Signaling Reduces PELP1-Mediated Tumor Growth and Therapy Resistance
Authors: Gonugunta Vijay K. , Sareddy Gangadhara R. , Krishnan Samaya Rajeshwari , Cortez Valerie , Roy Sudipa Saha , Tekmal Rajeshwar Rao , Vadlamudi Ratna K.
Published: April 2023

PDF 385K, mTOR inhibitors reduce the tamoxifen driven PELP1-mediated subcutaneous xenograft tumor growth.
Supplementary Figure 3 from Inhibition of mTOR Signaling Reduces PELP1-Mediated Tumor Growth and Therapy Resistance
Authors: Gonugunta Vijay K. , Sareddy Gangadhara R. , Krishnan Samaya Rajeshwari , Cortez Valerie , Roy Sudipa Saha , Tekmal Rajeshwar Rao , Vadlamudi Ratna K.
Published: April 2023

PDF - 106K, Synergistic effect of mTOR inhibitor and tamoxifen on therapy resistant cells.
Supplementary Figure 2 from Inhibition of mTOR Signaling Reduces PELP1-Mediated Tumor Growth and Therapy Resistance
Authors: Gonugunta Vijay K. , Sareddy Gangadhara R. , Krishnan Samaya Rajeshwari , Cortez Valerie , Roy Sudipa Saha , Tekmal Rajeshwar Rao , Vadlamudi Ratna K.
Published: April 2023

PDF - 115K, mTOR inhibitors reduce proliferation and promote apoptosis of PELP1-WT driven tumors.
Supplementary Figure 1 from Inhibition of mTOR Signaling Reduces PELP1-Mediated Tumor Growth and Therapy Resistance
Authors: Gonugunta Vijay K. , Sareddy Gangadhara R. , Krishnan Samaya Rajeshwari , Cortez Valerie , Roy Sudipa Saha , Tekmal Rajeshwar Rao , Vadlamudi Ratna K.
Published: April 2023

PDF - 226K, PELP1 down regulation or upregulation alters mTOR signaling and PELP1 interacts with mTOR.
Supplementary Figure 5 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
Authors: Eritja Nuria , Domingo Mónica , Dosil Maria Alba , Mirantes Cristina , Santacana Maria , Valls Joan , Llombart-Cussac Antonio , Matias-Guiu Xavier , Dolcet Xavier
Published: April 2023

PDF - 3065K, Uteri from mice treated during 15 days with Dovitinib (20mg/kg daily) and/or ICI182.780 (5mg/kg) were extracted. Immunostaining for ERalpha and Cyclin D1 was performed to ensure ICI182.780 treatment